A protein known as TL1A drives lung fibrosis, or scarring, in scleroderma, a new study suggests. The findings suggest that blocking TL1A could be an effective therapeutic strategy in scleroderma and other conditions characterized by lung fibrosis, including severe asthma, and idiopathic pulmonary fibrosis. Titled, “…
Muscular involvement is linked with more severe symptoms in people with scleroderma, affecting heart, lungs and the digestive system, a study from China reports. These patients are likely to have a worse disease prognosis and poorer survival, its data show. The study “Myopathy is a Risk Factor for…
Bob Saget will return to host the 34th annual Cool Comedy – Hot Cuisine fundraiser, benefiting the Scleroderma Research Foundation (SRF), on Sunday, Oct. 18. The comedian will be joined by celebrity chef and restaurateur Susan Feniger as co-host of the now online event.
Rituximab, in combination with CellCept (mycophenolate mofetil), reverses the decline in lung function in people with interstitial lung disease (ILD) associated with scleroderma (SSc) who did not respond to immunosuppressant therapies, a study suggested. The study, “…
Detailed characteristics of 12 cases of lung cancer in people with scleroderma were described in a new study. Notably, all patients were women and most had interstitial lung disease (ILD). The study, “Clinicopathological characteristics of lung cancer in patients with systemic sclerosis,” was published…
Treatment with lenabasum failed to outperform a placebo when given as an add-on to standard immunosuppressants in adults with diffuse cutaneous scleroderma (dcSSc), top-line data from a Phase 3 trial show. Participants given a placebo on top of immunosuppressants experienced an unprecedented improvement, Corbus Pharmaceuticals said in…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography competition to raise awareness for rare diseases. Under the theme “A Glimmer of Hope,” the competition is a means to “visually express the hope that exists for people affected by…
The Scleroderma Lung Study III (SLSIII), a Phase 2 clinical trial of oral CellCept (mycophenolate mofetil) alone or in combination with Esbriet (pirfenidone) in  scleroderma-associated interstitial lung disease (ILD) is enrolling patients. The trial (NCT03221257) is taking place across 17 clinical sites in the U.S., including the University…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input into research. The goal is to help the pharmaceutical industry deliver innovative new therapies faster and smarter, the…
People with scleroderma who lack disease-related autoantibodies show a clinically distinct profile, which includes younger age at disease onset, and differences in skin thickness and the proportion of patients with diffuse disease, a Japanese study has found. The study, “Clinical features of Japanese systemic sclerosis…
Get regular updates to your inbox.